The Use of Biologics During the COVID-19 Pandemic.
Dermatol Clin
; 39(4): 545-553, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1347570
ABSTRACT
During the coronavirus disease 2019 (COVID-19) pandemic, there has been considerable discussion regarding the use of biologics in patients with inflammatory skin conditions, such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. This article discusses clinical trial data, real-world evidence, and guidelines and recommendations for biologics that inhibit tumor necrosis factor, interleukin (IL)-12/23, IL-17, IL-23, and IL-4/13 during the COVID-19 pandemic. Across these inflammatory skin conditions, existing data generally suggest that biologics do not seem to increase the risk of COVID-19 infection or worsen COVID-19 outcomes. The impact of biologics on COVID-19 is an area of active exploration.
Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Enfermedades de la Piel
/
Productos Biológicos
/
Tratamiento Farmacológico de COVID-19
Tipo de estudio:
Estudio pronóstico
/
Ensayo controlado aleatorizado
Tópicos:
Covid persistente
Límite:
Humanos
Idioma:
Inglés
Revista:
Dermatol Clin
Año:
2021
Tipo del documento:
Artículo
País de afiliación:
J.det.2021.05.010
Similares
MEDLINE
...
LILACS
LIS